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Background/Aim: To describe a case of invasive orbital aspergillosis and evaluate 
treatments and outcomes.  
Methods: A case report and review of orbital aspergillosis treatment with voriconazole in the 
English language literature.  
Conclusion: Amphotericin B with debridement is the current standard of care for orbital 
aspergillosis; however, its prognosis is unfavorable. When compared to amphotericin B, 
voriconazole demonstrates a survival benefit, has less systemic toxicity, and is better 
tolerated by patients. While a prospective trial comparing amphotericin B to voriconazole in 




Orbital aspergillosis is a rare and often fatal condition in healthy patients. Due to its 
vague initial symptomatology, it is often misdiagnosed and improperly treated which, 
in turn, facilitates disease progression. Once proper treatment is initiated, the therapy 
is often poorly tolerated and the mortality rate remains high. 
In this case report, we will discuss a patient whose symptoms began in July 2010 and 
follow the historical, clinical, radiographic, and histological course until the diagnosis of 
invasive orbital aspergillosis was made in November 2010. We will then discuss 
treatment options presented to this patient and summarize treatment options in the 
context of the available literature. Case Rep Ophthalmol 2012;3:46–53 
DOI: 10.1159/000336276 
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A 68-year-old white man with a past medical history of glaucoma with remote bilateral 
trabeculectomies, hypertension, depression, and sinusitis presented with a 1-month history of 
headaches and pain around his right eye. The patient described the pain as a constant ache behind his 
right eye which, over the course of the month, had intensified to become a sharp, stabbing pain. 
During the third week, he began to have blurred vision and ptosis of the right lid. He sought treatment 
at his local hospital where he was admitted and had a head CT, a head MRI, and bilateral temporal 
artery biopsies. No pathology was seen on imaging, and the temporal artery biopsies were negative. 
As a result, the patient was presumptively diagnosed with giant cell arteritis (GCA) and treated with 
corticosteroids. He was subsequently discharged. 
The patient presented in our neuro-ophthalmology clinic 4 weeks after the initial onset of his 
symptoms. At this time, the patient’s medications consisted of Amlodipine, Valsartan, Paroxetine, 
Omeprazole, and Oxycodone. His best-corrected visual acuity was 20/60 OD and 20/25 OS; his color 
vision tested with Ishihara plates was 1/11 OD and 11/11 OS. On examination, he had a trace right 
relative afferent pupillary defect, complete ptosis of the right lid, and a frozen right eye due to 
paralysis of cranial nerves III, IV, and VI (fig. 1a). The combination of the visual and clinical findings 
led to the diagnosis of orbital apex syndrome. His trabeculectomy blebs were moderately elevated 
and avascular bilaterally. Fundus examination demonstrated pink optic nerves with a cup/disc ratio 
of 0.8 OD and 0.9 OS. The examination was otherwise unremarkable. 
The patient was immediately admitted to the hospital for further workup. We held corticosteroids 
due to the suspicion of an infectious etiology. Laboratory testing revealed a C-reactive protein level of 
7.9 mg/l, erythrocyte sedimentation rate of 46 mm/h, and white blood cell count of 6,900/µl with 
93% neutrophils. An MRI and CT of the head were ordered which demonstrated an infiltrative process 
centered in the right pterygopalatine fossa and involving the soft tissues of the nasal posterolateral 
recess, right orbital apex, right sphenoid sinus, and dura adjacent to the clinoid process (fig. 2). The 
infiltrative process was suggestive of a lymphomatous rather than fungal etiology. 
The Department of Otolaryngology was consulted, and a right trans-sphenoid orbital biopsy was 
performed. Preliminary pathology from the biopsy demonstrated an infiltrate consisting of a mixture 
of granulocytes, giant cells, and small mature lymphocytes without evidence of infection. The slides 
were considered suggestive of a nonspecific inflammatory etiology, such as Tolosa-Hunt syndrome, 
and were sent for further staining. The patient was discharged on prednisone 80 mg/day (1 mg/kg/ 
day). The following morning, a pathological examination revealed numerous septate hyphae 
branching at 45° angles consistent with Aspergillus. This finding was later confirmed by a culture 
positive for Aspergillus fumigatus. The patient was immediately notified and readmitted. 
Upon admission, the patient’s best-corrected visual acuity had deteriorated to 20/100 OD, and his 
right eye remained frozen. According to recommendations provided by the Division of Infectious 
Diseases, he was started on voriconazole 4 mg/kg i.v. The patient’s ophthalmoplegia and visual acuity 
improved dramatically within 72 h, and after 6 days of therapy the patient’s visual acuity was 20/40 
OD. There was resolution of his relative afferent pupillary defect and color vision deficits. He also 
showed a marked improvement in motility (fig. 1b). He was discharged on voriconazole 350 mg p.o. 
b.i.d., with close follow-up. 
After 6 weeks of treatment, the patient returned to our clinic with full extraocular movements, full 
color vision, and a visual acuity of 20/30 OD. An interval MRI of the orbits demonstrated an overall 
improvement. During this visit, the patient complained of a new rash on his trunk and upper 
extremities. The Divisions of Infectious Diseases and Dermatology were consulted, and it was found 
that the patient had developed a drug-induced photosensitivity rash secondary to voriconazole. His 
therapy was changed to daily intravenous micafungin 150 mg, which he has tolerated well for the last 
month. Case Rep Ophthalmol 2012;3:46–53 
DOI: 10.1159/000336276 
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Orbital aspergillosis is a rare infection in healthy individuals. Aspergillus is a 
ubiquitous species that resides in the soil. Approximately 5.7 × 107 Aspergillus spores 
are inhaled daily by the average American [1]. The best-established risk factor for 
orbital aspergillosis is sinusitis of a paraorbital sinus; however, there is no consensus 
on which loci confer the greatest risk [1–3]. Other risk factors include trauma, facial 
surgery, high-exposure professions (demolition, yard work, or working in endemic 
areas of Aspergillus flavus such as the Sudan), and immunocompromised states 
including AIDS, absolute neutrophil count <1,000, leukemia, and diabetes mellitus. 
The two most common pathogens in humans are A. flavus and A. fumigatus. In the 
orbit, A. flavus causes an invasive granulomatous infection, whereas A. fumigatus may 
present as a noninvasive or an invasive necrotizing-fulminate infection. Noninvasive 
orbital aspergillosis is typically found in diabetics, corticosteroid users, and 
immunocompetent individuals. There is typically a sparse immune response resulting 
in a slow indolent course. Patients often present with a chronic, dull retrobulbar pain 
present for months, headache, red eyes, and proptosis. Over time, these symptoms may 
progress to include sharp pain, cranial nerve palsies, amaurosis, and orbital apex 
syndrome. These symptoms can be temporarily ameliorated with steroids. As the 
disease progresses, Aspergillus may invade the vasculature resulting in necrotizing 
angiitis, mycotic aneurysms, dissemination, and thrombosis of the cavernous sinus, 
leading to mortality within days [2, 4]. As a result, aggressive early treatment of 
noninvasive infections is paramount. 
Invasive orbital aspergillosis presents similarly but with a more rapid progression 
and is uniformly fatal if untreated. Invasive aspergillosis typically manifests in 
immunocompromised individuals and is characterized by a granulomatous or 
fulminate immune response with a centrifugal invasion of adjacent tissues, vasculature, 
and bone. Invasive orbital aspergillosis may result in orbital apex syndrome, 
necrotizing angiitis, mycotic aneurysms, thrombosis, systemic dissemination, erosion of 
the orbit, and direct invasion of the central nervous system. When the disease is limited 
to the orbit, there is a 28% mortality rate for patients receiving standard treatment 
with amphotericin B [5]. However, once orbital apex syndrome has manifested, the 
mortality rate increases to 70–80% despite standard treatment, and if the central 
nervous system is involved, the mortality rate increases to 80–100% [4–7]. 
The diagnosis of orbital aspergillosis is difficult to confirm and is often delayed 2–10 
months from the initial presentation of symptoms [1]. Orbital aspergillosis should be 
suspected whenever a patient presents with painful ophthalmalgia. However, since its 
initial symptoms are vague, similar to more prevalent conditions, and respond to 
steroids, aspergillosis is often misdiagnosed as orbital pseudotumor or GCA (table 1). 
Many patients, including ours, are presumptively started on corticosteroids and 
demonstrate a subsequent improvement resulting in a premature conclusion to the 
workup. Steroids decrease the inflammation in the orbit and transiently improve 
symptoms but may hasten the course of aspergillosis. 
When a diagnosis of orbital aspergillosis is suspected, an MRI of the orbit is 
indicated. MRI is useful for evaluating the optic nerve, cerebral dura, paraorbital 
sinuses, and masses. Any sinusitis (>8-mm thickening of the sinus mucosa) with an Case Rep Ophthalmol 2012;3:46–53 
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enhancement of the optic nerve or erosion of the orbital bones should prompt 
suspicion for orbital aspergillosis. A CT of the orbit without contrast may aid in the 
diagnosis by screening for bony erosion and examining for intraluminal calcification, 
which is pathognomonic. To confirm the diagnosis, a biopsy is required. Fungal cultures 
of the nares have been shown to be unreliable and should not be used for screening [2]. 
If imaging reveals a paraorbital sinusitis, an anterior rhinoscopy as well as a biopsy 
may be performed. While anterior rhinoscopy is the least invasive approach, 50% of 
cases require a second biopsy [1, 8]. Alternative approaches include orbital fine needle 
aspiration or trans-sinus orbital biopsy; these approaches have a higher yield but are 
more invasive than anterior rhinoscopy. The tissue should be sent for both frozen and 
permanent sections to look for fungi as well as other pathology. In addition, slides 
should be sent for periodic acid-Schiff stain and Gomori methenamine silver stain to 
look for haemotoxophilic organisms with 45° branching septate hyphae 2–4 µm in 
width. Cultures should be incubated for at least 30 days. If pathological testing is 
initially negative but a high suspicion of aspergillosis is maintained, corticosteroids 
should be held until cultures are known and empiric treatment for aspergillosis should 
be initiated. 
Treatment for orbital aspergillosis in the literature is based upon previous case 
reports. There are no prospective studies evaluating the efficacy of treatments in 
orbital aspergillosis. The current mainstay of therapy for orbital aspergillosis is 
amphotericin B i.v. 0.5 mg/kg/day with debridement of focal abscesses [1, 2, 4]. In 
total, 40–60% of patients show a response to amphotericin B, including liposomal 
preparations [1]. Despite treatment with amphotericin B, once the infection has 
manifested as an orbital apex syndrome, the mortality rate remains 70–80% [1, 2, 4–6]. 
Due to a high rate of relapse, prolonged treatment for 2 years to life is suggested [1, 2]. 
Amphotericin B has numerous side effects, including irreversible nephrotoxicity, and as 
a result is often poorly tolerated. There is a case report of a patient who died as a direct 
result of amphotericin B therapy for invasive orbital aspergillosis [8]. 
Alternative therapies in the literature include itraconazole 200–400 mg/day. 
Itraconazole is better tolerated than amphotericin B, but has similar response, relapse, 
and mortality rates [1, 4]. This drug should not be used if there is pulmonary 
involvement because a higher mortality has been demonstrated in these cases. 
Concomitant induction of amphotericin B and itraconazole may increase response, and 
maintenance with itraconazole alone is significantly better tolerated than with 
amphotericin B [4]. Fluconazole 100–200 mg/kg/day and rifampin 600 mg/day have 
also been shown to be effective, but there are too few reports to evaluate their role in 
therapy [4, 9]. Ketoconazole on the other hand has been shown to be ineffective in 
treating orbital aspergillosis [4]. 
Voriconazole is a second-generation triazole antifungal that has become the usual 
treatment of extraorbital invasive aspergillosis after demonstrating a 22% survival 
benefit over amphotericin B in a comparative evaluation [10, 11]. Voriconazole 
6 mg/kg for 1 day, then 4 mg/kg/day, has less systemic side effects than amphotericin 
B, favorable bone penetration, and is better tolerated for maintenance therapy [10–12]. 
Despite its favorable profile, we could only find one case report in the English literature 
and two abstracts in the Japanese literature on voriconazole treatment of invasive 
orbital aspergillosis [10, 13, 14]. In each of these case reports, the patients 
demonstrated a dramatic improvement within several days of voriconazole therapy. Case Rep Ophthalmol 2012;3:46–53 
DOI: 10.1159/000336276 
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In the English literature, Sasindran et al. [10] presented a case of an 8-year-old boy 
who developed an orbital apex syndrome after a trauma. He was initially treated with 
steroids; however, his symptoms worsened. A biopsy was obtained revealing A. flavus 
infection. He was successfully treated with 150 mg voriconazole b.i.d. for 12 months. 
The Japanese literature presented 2 cases of patients in their 70s being successfully 
treated for orbital aspergillosis, but the treatment protocols were not discussed in the 
abstracts [13, 14]. 
Conclusion 
Despite being the current standard of treatment for invasive orbital aspergillosis, 
amphotericin B preparations offer an unfavorable prognosis. With optimized 
amphotericin B therapy, the mortality rate in orbital apex syndrome patients remains 
70–80%. Additionally, only 40–60% of patients with orbital aspergillosis will respond 
to treatment with amphotericin B, and patients poorly tolerate prolonged therapy. Most 
patients develop serious complications such as nephrotoxicity, and 1 patient is 
reported to have died as a direct result of the therapy [8]. 
While the role of voriconazole as the mainstay of therapy for extraorbital invasive 
aspergillosis is well defined, its role in orbital aspergillosis has not yet been 
documented. The use of voriconazole seems intuitive for orbital aspergillosis since it 
confers a survival benefit, provides better bone penetration, and is better tolerated 
than amphotericin B preparations in extraorbital invasive aspergillosis. The efficacy of 
voriconazole has been demonstrated in our patient and the 3 above-mentioned case 
reports found in the literature. Each patient reported a quick response, dramatic 
symptom improvement, and no relapses. Out of the 4 patients, only our patient 
reported a side effect (photosensitive drug rash) due to voriconazole. 
Our patient’s risk factors for orbital aspergillosis included type 2 diabetes and a 
history of previous sinusitis. These risk factors are usually associated with noninvasive 
orbital aspergillosis rather than with the invasive disease as confirmed by MRI in our 
case. Our patient may initially have had a noninvasive orbital aspergillosis that was 
exacerbated by the use of corticosteroids for the treatment of probable GCA. The 
reversible immunosuppression conferred by the steroids may explain the rapid 
invasive progression and the favorable response to voriconazole. 
While 4 patients do not demonstrate a statistical benefit, voriconazole can be 
considered an efficacious alternative to amphotericin B for the treatment of orbital 
aspergillosis that is better tolerated by patients. 
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Table 1. Differential diagnosis 
Inflammatory  Idiopathic orbital inflammation 
Tolosa-Hunt syndrome 
Sarcoidosis 




Other fungi (Mucor, Fusarium) 
        Vasculitis  Giant cell arteritis 
Wegener’s arteritis 
        Neoplastic  B cell lymphoma 
Primary orbital tumors 
        Neuro-ophthalmic  Optic neuritis 





Fig. 1. a Extraocular movements prior to treatment, demonstrating an orbital apex syndrome. 
b Eye movements after 2 weeks of voriconazole therapy. 
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Fig. 2.  MRI T1- (a) and T2-weighted (b) images from our patient, demonstrating an infiltrative process 
centered in the right pterygopalatine fossa and involving the adjacent soft tissues of the nasal 
posterolateral recess, right orbital apex, right sphenoid sinus, and dura of the clinoid process. 
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